FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320734475> ?p ?o ?g. }

• W4320734475 endingPage "168" @default.
• W4320734475 startingPage "168" @default.
• W4320734475 abstract "Invasive breast carcinomas (BRCAs) are highly lethal. The molecular mechanisms underlying progression of invasive BRCAs are unclear, and effective therapies are highly desired. The cancer-testis antigen CT45A1 promotes overexpression of pro-metastatic sulfatase-2 (SULF2) and breast cancer metastasis to the lungs, but its mechanisms are largely unknown. In this study, we aimed to elucidate the mechanism of CT45A1-induced SULF2 overexpression and provide evidence for targeting CT45A1 and SULF2 for breast cancer therapy.The effect of CT45A1 on SULF2 expression was assessed using reverse transcription polymerase chain reaction and western blot. The mechanism of CT45A1-induced SULF2 gene transcription was studied using protein-DNA binding assay and a luciferase activity reporter system. The interaction between CT45A1 and SP1 proteins was assessed using immunoprecipitation and western blot. Additionally, the suppression of breast cancer cell motility by SP1 and SULF2 inhibitors was measured using cell migration and invasion assays.CT45A1 and SULF2 are aberrantly overexpressed in patients with BRCA; importantly, overexpression of CT45A1 is closely associated with poor prognosis. Mechanistically, gene promoter demethylation results in overexpression of both CT45A1 and SULF2. CT45A1 binds directly to the core sequence GCCCCC in the promoter region of SULF2 gene and activates the promoter. Additionally, CT45A1 interacts with the oncogenic master transcription factor SP1 to drive SULF2 gene transcription. Interestingly, SP1 and SULF2 inhibitors suppress breast cancer cell migration, invasion, and tumorigenicity.Overexpression of CT45A1 is associated with poor prognosis in patients with BRCA. CT45A1 promotes SULF2 overexpression by activating the promoter and interacting with SP1. Additionally, SP1 and SULF2 inhibitors suppress breast cancer cell migration, invasion, and tumorigenesis. Our findings provide new insight into the mechanisms of breast cancer metastasis and highlight CT45A1 and SULF2 as sensible targets for developing novel therapeutics against metastatic breast cancer." @default.
• W4320734475 created "2023-02-15" @default.
• W4320734475 creator A5000399343 @default.
• W4320734475 creator A5002453000 @default.
• W4320734475 creator A5009953193 @default.
• W4320734475 creator A5016683563 @default.
• W4320734475 creator A5017269103 @default.
• W4320734475 creator A5021578970 @default.
• W4320734475 creator A5048333692 @default.
• W4320734475 date "2023-01-01" @default.
• W4320734475 modified "2023-10-15" @default.
• W4320734475 title "The Cancer/Testis Antigen CT45A1 Promotes Transcription of Oncogenic <i>Sulfatase-2</i> Gene in Breast Cancer Cells and Is Sensible Targets for Cancer Therapy" @default.
• W4320734475 cites W1635672209 @default.
• W4320734475 cites W1978405139 @default.
• W4320734475 cites W1986033915 @default.
• W4320734475 cites W1994503647 @default.
• W4320734475 cites W2002256470 @default.
• W4320734475 cites W2016927165 @default.
• W4320734475 cites W2017678291 @default.
• W4320734475 cites W2029816755 @default.
• W4320734475 cites W2048358455 @default.
• W4320734475 cites W2049612034 @default.
• W4320734475 cites W2067047341 @default.
• W4320734475 cites W2080215179 @default.
• W4320734475 cites W2126282065 @default.
• W4320734475 cites W2132899220 @default.
• W4320734475 cites W2155826575 @default.
• W4320734475 cites W2170138004 @default.
• W4320734475 cites W2291386100 @default.
• W4320734475 cites W2301345352 @default.
• W4320734475 cites W2507992840 @default.
• W4320734475 cites W2528508895 @default.
• W4320734475 cites W2597080164 @default.
• W4320734475 cites W2754757241 @default.
• W4320734475 cites W2887408665 @default.
• W4320734475 cites W2892030326 @default.
• W4320734475 cites W2920825919 @default.
• W4320734475 cites W2945673033 @default.
• W4320734475 cites W2965576600 @default.
• W4320734475 cites W2969263349 @default.
• W4320734475 cites W3005323518 @default.
• W4320734475 cites W3009742610 @default.
• W4320734475 cites W3037907537 @default.
• W4320734475 cites W3082714866 @default.
• W4320734475 cites W3083587137 @default.
• W4320734475 cites W3133794211 @default.
• W4320734475 cites W3136675908 @default.
• W4320734475 cites W3157341386 @default.
• W4320734475 cites W3159317527 @default.
• W4320734475 cites W3161491075 @default.
• W4320734475 cites W3170283419 @default.
• W4320734475 cites W3174797440 @default.
• W4320734475 cites W3195237310 @default.
• W4320734475 cites W3200020192 @default.
• W4320734475 cites W4226467551 @default.
• W4320734475 cites W4231356616 @default.
• W4320734475 cites W4256201550 @default.
• W4320734475 cites W577252653 @default.
• W4320734475 doi "https://doi.org/10.4048/jbc.2023.26.e5" @default.
• W4320734475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37095619" @default.
• W4320734475 hasPublicationYear "2023" @default.
• W4320734475 type Work @default.
• W4320734475 citedByCount "1" @default.
• W4320734475 crossrefType "journal-article" @default.
• W4320734475 hasAuthorship W4320734475A5000399343 @default.
• W4320734475 hasAuthorship W4320734475A5002453000 @default.
• W4320734475 hasAuthorship W4320734475A5009953193 @default.
• W4320734475 hasAuthorship W4320734475A5016683563 @default.
• W4320734475 hasAuthorship W4320734475A5017269103 @default.
• W4320734475 hasAuthorship W4320734475A5021578970 @default.
• W4320734475 hasAuthorship W4320734475A5048333692 @default.
• W4320734475 hasBestOaLocation W43207344751 @default.
• W4320734475 hasConcept C101762097 @default.
• W4320734475 hasConcept C104317684 @default.
• W4320734475 hasConcept C121608353 @default.
• W4320734475 hasConcept C134320426 @default.
• W4320734475 hasConcept C150194340 @default.
• W4320734475 hasConcept C2776415932 @default.
• W4320734475 hasConcept C2779013556 @default.
• W4320734475 hasConcept C502942594 @default.
• W4320734475 hasConcept C530470458 @default.
• W4320734475 hasConcept C54355233 @default.
• W4320734475 hasConcept C57467964 @default.
• W4320734475 hasConcept C86339819 @default.
• W4320734475 hasConcept C86803240 @default.
• W4320734475 hasConceptScore W4320734475C101762097 @default.
• W4320734475 hasConceptScore W4320734475C104317684 @default.
• W4320734475 hasConceptScore W4320734475C121608353 @default.
• W4320734475 hasConceptScore W4320734475C134320426 @default.
• W4320734475 hasConceptScore W4320734475C150194340 @default.
• W4320734475 hasConceptScore W4320734475C2776415932 @default.
• W4320734475 hasConceptScore W4320734475C2779013556 @default.
• W4320734475 hasConceptScore W4320734475C502942594 @default.
• W4320734475 hasConceptScore W4320734475C530470458 @default.
• W4320734475 hasConceptScore W4320734475C54355233 @default.
• W4320734475 hasConceptScore W4320734475C57467964 @default.
• W4320734475 hasConceptScore W4320734475C86339819 @default.
• W4320734475 hasConceptScore W4320734475C86803240 @default.

• next